| 姚舒洋,张 毅.循环肿瘤DNA监测早期肺癌术后微小残留病灶的研究进展[J].肿瘤学杂志,2023,29(1):66-70. |
| 循环肿瘤DNA监测早期肺癌术后微小残留病灶的研究进展 |
| Circulating Tumor DNA in Predicting Minimal Residual Disease of Patients with Early-Stage Non-Small Cell Lung Cancer |
| 投稿时间：2022-05-20 |
| DOI：10.11735/j.issn.1671-170X.2023.01.B012 |
|
 |
|
| 中文关键词: 非小细胞肺癌 微小残留病灶 循环肿瘤DNA 液体活检 |
| 英文关键词:non-small cell lung cancer minimal residual disease circulating tumor DNA liquid biopsy |
| 基金项目:2021年吴阶平医学基金会资助（320.6750.2021-23-4） |
|
| 摘要点击次数: 453 |
| 全文下载次数: 224 |
| 中文摘要: |
| 摘 要：循环肿瘤DNA(circulating tumor DNA，ctDNA)已经应用于监测转移性非小细胞肺癌（non-small cell lung cancer，NSCLC）的治疗。近来研究者开始关注ctDNA预测早期NSCLC患者根治术后微小残留病灶(minimal residual disease，MRD) 的价值。全文总结目前常用的ctDNA检测方法，并介绍了其在早期肺癌术后评估MRD和复发预警方面的应用进展。 |
| 英文摘要: |
| Abstract： Circulating tumor DNA(ctDNA) has been widely used in monitoring efficacy of targeted therapy for metastatic non-small-cell lung cancer(NSCLC). Recent researches are focusing on the value of ctDNA in predicting minimal residual disease(MRD) of patients with early-stage cancer after treatment. This article reviews the techniques for detecting ctDNA and its application in monitoring MRD and recurrence in patients with early-stage NSCLC after radical resection. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |